TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$92.5 Million

Aura Biosciences, Inc.

Follow-on Offering

Bookrunner, November 2022

Aura Biosciences, Inc.

Aura Biosciences, Inc. (“Aura” or the “Company”) (AURA) is a clinical-stage biotechnology company envisioning a new way to treat cancer. Leveraging the Company’s novel targeted oncology platform, Aura has the goal to develop a new standard of care across multiple cancer indications. The Company’s initial focus is on ocular and urologic oncology where the disease is diagnosed early and there is a high unmet medical need. Aura’s proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. The Company’s VDCs are largely agnostic to tumor type and can recognize tumor associated glycosaminoglycans with unique heparan sulphate epitopes that are expressed on the cell surface of many tumor cells and in the tumor microenvironment.